Table 2.
Toxicity from DEB-TACE
| Variable | Value |
|---|---|
| Blood and lymphatic system disorders | |
| Neutropenia, Grade 1 | 1 (2.63) |
| Thrombocytopenia, Grade 1 | 1 (2.63) |
| Gastrointestinal disorders | |
| Abdominal pain | 6 (15.79) |
| Ascites | 5 (13.16) |
| Duodenal ulcer hemorrhage | 1 (2.63) |
| Nausea | 1 (2.63) |
| Esophageal variceal progression | 1 (2.63) |
| General disorders and administration site condition | |
| Pyrexia | 15 (39.47) |
| Hepatobiliary disorders | |
| Cholangitis | 1 (2.63) |
| Metabolism and nutrition disorders | |
| Decreased appetite | 1 (2.63) |
| Musculoskeletal and connective tissue disorders | |
| Back pain | 1 (2.63) |
| Pain in extremity | 1 (2.63) |
| Nervous system disorders | |
| Cerebellar infarction | 1 (2.63) |
| Respiratory, thoracic and mediastinal disorders | |
| Pulmonary embolism | 1 (2.63) |
| Skin and subcutaneous tissue disorders | |
| Pruritus | 1 (2.63) |
| Total | 38 (100.00) |
Values are presented as number (%).
DEB-TACE, drug-eluting bead transarterial chemoembolization.